semaglutide immunogenicity Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy Immunogenicity Risks in GLP-1 Peptide

These data provide confidence to proceed to a phase 3 trial in idiopathic intracranial hypertension and highlight the potential to utilize GLP-1 receptor agonist in other conditions characterized by raised intracranial pressure

Depression and mood changes are also listed as potential side effects

Sensitivity analyses indicated that conclusions were primarily influenced by discounting and long-term weight trajectory assumptions

Respondents who tried popular drugs that can lead to weight loss including tirzepatide (Mounjaro, Zepbound), semaglutide (Ozempic, Wegovy), and liraglutide (Saxenda) cited them as the best way to lose weight